Mechanisms of desensitization of vasodilatation induced by platelet-activating factor in hypertensive rats

被引:3
|
作者
Kamata, K
Numazawa, T
Kasuya, Y
机构
[1] Dept. of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Tokyo 142, Shinagawa-ku
关键词
PAF (platelet-activating factor); desensitization; spontaneously hypertensive rat (SHR); renal hypertensive rat (RHR); GTP-binding protein;
D O I
10.1016/0014-2999(96)00026-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We found that vasodilator effects of platelet-activating factor (PAF) on the mesenteric arterial bed of the rat were significantly attenuated in spontaneously hypertensive rats (SHR) and renal hypertensive rats (RHR). Perfusion of the mesentery with acetylcholine and PAF caused endothelium-dependent vasodilatation accompanied by an increase in cyclic GMP levels in the mesentery from normotensive Wistar Kyoto rats (WKY). Acetylcholine caused a significant increase in cyclic GMP levels in the effluent in both SHR and RHR, whereas PAF could not increase cyclic GMP levels in SHR and slightly increased cyclic GMP in RHR. Incubating the mesentery with PAF markedly inhibited the vasodilatation induced by PAF, but not acetylcholine or sodium nitroprusside. The cyclic GMP accumulation in the effluent was impaired in the mesenteric arterial bed pretreated with PAF and in that obtained from rats given islet-activating protein (IAP). The PAF-induced vasodilatation was completely reversed by the PAF receptor antagonist, CV-6209 (2-[N-acetyl-N-(2-methyl-3-octadecylcarbamoyl-oxypropoxycarbonyl)aminomethyl]-1-ethylpyridinium chloride). These results suggest that (1) attenuated vasodilator effects of PAF and decreased cyclic GMP levels in the mesentery from SHR and RHR are due to desensitization but not to impairment of the endothelium; (2) GTP-binding protein, which is IAP-sensitive, may be involved in PAF-induced vasodilatation and cyclic GMP accumulation; (3) desensitization of the mesentery to PAF in SHR and RHR may be due to PAF receptor and GTP-binding protein uncoupling.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [21] Effect of orthovanadate on platelet aggregation induced by platelet-activating factor
    Suenaga, A
    Ueki, H
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (11) : 1859 - 1863
  • [22] DESENSITIZATION OF PLATELET-ACTIVATING FACTOR-STIMULATED PROTEIN-PHOSPHORYLATION IN PLATELETS
    SHUKLA, SD
    MORRISON, WJ
    DHAR, A
    MOLECULAR PHARMACOLOGY, 1989, 35 (04) : 409 - 413
  • [23] CHARACTERIZATION OF CUTANEOUS VASCULAR-PERMEABILITY INDUCED BY PLATELET-ACTIVATING FACTOR IN GUINEA-PIGS AND RATS AND ITS INHIBITION BY A PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONIST
    HWANG, SB
    LI, CL
    LAM, MH
    SHEN, TY
    LABORATORY INVESTIGATION, 1985, 52 (06) : 617 - 630
  • [24] Mechanisms underlying the nociceptive responses induced by platelet-activating factor (PAF) in the rat paw
    Marotta, Denise M.
    Costa, Robson
    Motta, Emerson M.
    Fernandes, Elizabeth S.
    Medeiros, Rodrigo
    Quintao, Nara L. M.
    Campos, Maria M.
    Calixto, Joao B.
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (07) : 1223 - 1235
  • [25] Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung
    Uhlig, S
    Göggel, R
    Engel, S
    PHARMACOLOGICAL REPORTS, 2005, 57 : 206 - 221
  • [26] PLATELET-ACTIVATING FACTOR AND ASTHMA
    BARNES, PJ
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1988, 81 (01) : 152 - 160
  • [27] Platelet-Activating Factor and Pain
    Tsuda, Makoto
    Tozaki-Saitoh, Hidetoshi
    Inoue, Kazuhide
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (08) : 1159 - 1162
  • [28] Platelet-activating factor acetylhydrolase
    Arai, H
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 : 83 - 94
  • [29] NEPHROPATHIES AND PLATELET-ACTIVATING FACTOR
    PIROTZKY, E
    COLLIEZ, P
    GUILMARD, C
    BRAQUET, P
    PEDIATRIE, 1989, 44 (03): : 163 - 167
  • [30] Platelet-activating factor and angiogenesis
    Camussi, G
    Montrucchio, G
    Lupia, E
    Arese, M
    Bussolino, F
    PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2: ROLES IN HEALTH AND DISEASE, 1996, 416 : 231 - 234